Why Did Buffett Sell So Much Last Year?
In 2024, value investing legend Warren Buffett did the seemingly…
Buy
80
VIR Quote, Financials, Valuation and Earnings
Last price:
$10.50
Seasonality move
:
27.75%
Day range:
$12.02 - $13.74
52-week range:
$6.56 - $14.45
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
26.47x
P/B ratio:
1.34x
Volume:
6.5M
Avg. volume:
2.8M
1-year change:
17.36%
Market cap:
$1.7B
Revenue:
$39.5M
EPS (TTM):
-$3.92
Analysts' Opinion
-
Consensus RatingVir Biotechnology has received a consensus rating of Leans Bullish. The company's average rating is a Leans Bullish based on 2 Buy ratings, 2 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $31.38, Vir Biotechnology has an estimated upside of 157.23% from its current price of $12.10.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $14.00 representing -15.7% downside risk from its current price of $12.10.
Fair Value
-
According to the consensus of 4 analysts, Vir Biotechnology has 157.23% upside to fair value with a price target of $31.38 per share.
VIR vs. S&P 500
-
Over the past 5 trading days, Vir Biotechnology has overperformed the S&P 500 by 69.73% suggesting its relative strength compared to the major market average is strong at this time.
Share Buyback
-
Vir Biotechnology does not have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Vir Biotechnology has grown year-over-year revenues for 1 quarter straight. In the most recent quarter Vir Biotechnology reported revenues of $289K.
Earnings Growth
-
Vir Biotechnology has grown year-over-year earnings for 0 quarters straight. In the most recent quarter Vir Biotechnology reported earnings per share of -$1.56.
Enterprise value:
751.9M
EV / Invested capital:
--
Price / LTM sales:
26.47x
EV / EBIT:
--
EV / Revenue:
12.12x
PEG ratio (5yr expected):
-0.03x
EV / Free cash flow:
-1.59x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
$61.1M
Return On Assets:
-29.88%
Net Income Margin (TTM):
-859.73%
Return On Equity:
-35.62%
Return On Invested Capital:
-35.62%
Operating Margin:
-75637.37%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2023-09-30 | 2024-09-30 | |
| Income Statement | ||||||
| Revenue | $2.4B | $51.7M | $62M | -$4.1M | $289K | |
| Gross Profit | $2.2B | $43.7M | $61.1M | -$4.1M | $239K | |
| Operating Income | $1.6B | -$687.1M | -$578.8M | -$183.4M | -$218.6M | |
| EBITDA | $1.6B | -$670.1M | -$562.6M | -$178.8M | -$215.7M | |
| Diluted EPS | $8.49 | -$4.49 | -$3.92 | -$1.22 | -$1.56 | |
| Period Ending | 2020-09-30 | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $849.6M | $1.1B | $2.4B | $1.8B | $1B | |
| Total Assets | $943.3M | $1.2B | $2.7B | $2B | $1.5B | |
| Current Liabilities | $77M | $233.7M | $308.2M | $165.1M | $117.2M | |
| Total Liabilities | $130.9M | $333.9M | $546.1M | $369.8M | $257.6M | |
| Total Equity | $812.4M | $876.3M | $2.1B | $1.7B | $1.2B | |
| Total Debt | -- | -- | -- | -- | -- | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2023-09-30 | 2024-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | $1.6B | -$635.7M | -$466.6M | -$155.8M | -$171.5M | |
| Cash From Investing | -$1.4B | $116.3M | $253.8M | -$59M | $118.6M | |
| Cash From Financing | $38.4M | $7.8M | $4.8M | $277K | $31K | |
| Free Cash Flow | $1.6B | -$668.3M | -$473.1M | -$159.5M | -$173.8M | |
VIR
Sector
Market Cap
$1.7B
$47.5M
Price % of 52-Week High
83.74%
47.33%
Dividend Yield
0%
0%
Shareholder Yield
--
-0.74%
1-Year Price Total Return
17.36%
-34.04%
Beta (5-Year)
0.510
0.752
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Technicals
8-day SMA
Buy
Level
$8.73
200-day SMA
Buy
Level
$8.76
Bollinger Bands (100)
Buy
Level
7.09 - 8.93
Chaikin Money Flow
Sell
Level
-82.7M
20-day SMA
Buy
Level
$7.95
Relative Strength Index (RSI14)
Buy
Level
78.81
ADX Line
Buy
Level
36.42
Williams %R
Neutral
Level
-31.7139
50-day SMA
Buy
Level
$8.17
MACD (12, 26)
Buy
Level
0.60
25-day Aroon Oscillator
Buy
Level
52
On Balance Volume
Neutral
Level
15.8M
Financial Scores
Hold
Altman Z-Score
(Annual)
Level (2.0279)
Sell
CA Score
(Annual)
Level (-0.4945)
--
Beneish M-Score
(Annual)
Level (--)
Buy
Momentum Score
Level (3)
Sell
Ohlson Score
Level (0.429)
Sell
Piotroski F Score
(Annual)
Level (3)
Sell
Quality Ratio Score
Level (1)
Buy
Fundamental Score
Level (5)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Vir Biotechnology Inc is an immunology company focused on combining cutting-edge technologies to treat and prevent serious infectious diseases and other serious conditions, including viral-associated diseases. Through internal development, collaborations, and acquisitions, it has four technology platforms, focused on antibodies, T cells, innate immunity, and small interfering ribonucleic acid, or siRNA. The company's pipeline consists of product candidates targeting hepatitis B, HBV, influenza A, human immunodeficiency virus, HIV, and tuberculosis, or TB. Its revenue sources are collaboration revenue, contract revenue, grant revenue, and license revenue.
Stock Forecast FAQ
In the current month, VIR has received 2 Buy ratings 2 Hold ratings, and 0 Sell ratings. The VIR average analyst price target in the past 3 months is $31.38.
-
Where Will Vir Biotechnology Stock Be In 1 Year?
According to analysts, the consensus estimate is that Vir Biotechnology share price will rise to $31.38 per share over the next 12 months.
-
What Do Analysts Say About Vir Biotechnology?
Analysts are divided on their view about Vir Biotechnology share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Vir Biotechnology is a Sell and believe this share price will drop from its current level to $14.00.
-
What Is Vir Biotechnology's Price Target?
The price target for Vir Biotechnology over the next 1-year time period is forecast to be $31.38 according to 4 Wall Street analysts, 2 of them rate the stock a Buy, 0 rate the stock a Sell, and 2 analysts rate the stock a Hold.
-
Is VIR A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Vir Biotechnology is a Leans Bullish. 2 of 4 analysts rate the stock a Leans Bullish at this time.
-
How Can I Buy Shares Of VIR?
You can purchase shares of Vir Biotechnology via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, TastyTrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Vir Biotechnology shares.
-
What Is The Vir Biotechnology Share Price Today?
Vir Biotechnology was last trading at $10.50 per share. This represents the most recent stock quote for Vir Biotechnology. Yesterday, Vir Biotechnology closed at $12.10 per share.
-
How To Buy Vir Biotechnology Stock Online?
In order to purchase Vir Biotechnology stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is American Tower Stock Undervalued?
The market action of late has been nothing short of…
Is Broadcom Stock Overvalued?
The semiconductor company Broadcom Inc. (NASDAQ:AVGO) is having a stellar…
Stock Ideas
Sell
48
Is AAPL Stock a Buy?
Market Cap: $3.6T
P/E Ratio: 39x
Sell
47
Is NVDA Stock a Buy?
Market Cap: $3.3T
P/E Ratio: 114x
Sell
39
Is MSFT Stock a Buy?
Market Cap: $3.1T
P/E Ratio: 36x
Alerts
Buy
87
CEG alert for Jan 13
Constellation Energy [CEG] is down 8.54% over the past day.
Sell
1
MCY alert for Jan 13
Mercury General [MCY] is down 2.86% over the past day.
Buy
84
ATZAF alert for Jan 13
Aritzia [ATZAF] is down 4.41% over the past day.
